Contemporary Tailored Oncology Treatment of Biliary Tract Cancers
Biliary tract cancers (BTCs) are poor prognosis malignancies with limited treatment options. Capecitabine has recently emerged as an effective agent in the adjuvant setting; however, treatment of advanced disease is still limited to first-line cisplatin and gemcitabine chemotherapy. Recent global ef...
Saved in:
| Main Authors: | Fiona Turkes, Juliet Carmichael, David Cunningham, Naureen Starling |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2019/7698786 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biliary tract cancers – single institution retrospective analysis, a cross-section of epidemiological data with treatment patterns and the outcomes of biliary tract cancers at the Department of Oncology and Radiotherapy, University Hospital Split from 2019-2022
by: Suzana Bratić, et al.
Published: (2024-01-01) -
T‐Cadherin in Biliary Tract Cancer Stroma, a Potent Pharmacological Target for Biliary Tract Carcinogenesis
by: Yuki Hanamatsu, et al.
Published: (2025-04-01) -
Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives
by: Marco Imperatori, et al.
Published: (2016-01-01) -
Biliary tract cancers: advances in diagnostic and management
by: James Gutmans, et al.
Published: (2025-06-01) -
Pregnancy and the Biliary Tract
by: Tuvia Gilat, et al.
Published: (2000-01-01)